Get the Stockscreener App
71.93
0.75%
-0.54
After Hours:
72.28
0.35
+0.49%
Incyte Corp stock is traded at $71.93, with a volume of 950.11K.
It is down -0.75% in the last 24 hours and up +3.65% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$72.47
Open:
$72.87
24h Volume:
950.11K
Relative Volume:
0.51
Market Cap:
$13.86B
Revenue:
$4.08B
Net Income/Loss:
$32.48M
P/E Ratio:
513.79
EPS:
0.14
Net Cash Flow:
$16.80M
1W Performance:
+1.97%
1M Performance:
+3.65%
6M Performance:
+10.15%
1Y Performance:
+17.00%
1-Day Range:
$71.85
$73.00
1-Week Range:
$69.65
$73.83
52-Week Range:
$50.35
$83.95
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
71.93 | 13.86B | 4.08B | 32.48M | 16.80M | 0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Incyte Gains 15.3% In A Year: Is There Room For Further Growth? - Barchart
Short Interest in Incyte Co. (NASDAQ:INCY) Decreases By 13.1% - MarketBeat
INCY (Incyte) GF Value Rank : 8 (As of Jan. 20, 2025) - GuruFocus.com
Hennion & Walsh Asset Management Inc. Purchases 11,120 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
What You Need To Know Ahead Of Incyte's Earnings Release - Barchart
Fed. Circ. Urged To Keep Block Of Sun Pharma Alopecia Drug - Law360
Contravisory Investment Management Inc. Has $750,000 Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
CHURCHILL MANAGEMENT Corp Has $12.36 Million Stock Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
Claro Advisors LLC Takes Position in Incyte Co. (NASDAQ:INCY) - MarketBeat
JP Morgan 2025: Incyte expects period of ‘defining catalysts’ - Yahoo Finance
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Warm Autoimmune hemolytic anemia (WAIHA) Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Rigel Pharma, Incyte Crp., Sanofi, Johnson & Johnson, Janssen R&D - Barchart
Incyte's SWOT analysis: navigating patent cliff with promising pipeline - Investing.com
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
DPP-led Effort For Incyte Leads To Deal Of The Year Honors - Town Square Delaware LIVE
Incyte's (INCY) "Market Perform" Rating Reiterated at JMP Securities - MarketBeat
Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline - Benzinga
Warm Autoimmune hemolytic anemia (WAIHA) Market Poised - openPR
Pallas Capital Advisors LLC Makes New $1.01 Million Investment in Incyte Co. (NASDAQ:INCY) - MarketBeat
Has Incyte (INCY) Outpaced Other Medical Stocks This Year? - MSN
Anal Cancer Market on Track for Major Expansion by 2034, - openPR
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Analysts Set Incyte Co. (NASDAQ:INCY) Target Price at $76.29 - MarketBeat
Incyte: Multiple Drug Launches Bode Well For Future Growth - Seeking Alpha
Incyte (NASDAQ:INCY) Given "Neutral" Rating at Cantor Fitzgerald - MarketBeat
Incyte Corporation (INCY) Announces Executive Leadership Change - GuruFocus.com
Incyte Announces Retirement of Executive VP Barry Flannelly - TipRanks
JPMorgan Chase & Co. Reduces Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2025 - BioSpace
Incyte (MEX:INCY) Earnings Yield % : 0.09% (As of Jan. 08, 2025) - GuruFocus.com
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
Follicular Lymphoma Market Expected to rise, 2034 | - openPR
CWA Asset Management Group LLC Acquires Shares of 27,984 Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock rises Friday, still underperforms market - MarketWatch
Centre Asset Management LLC Has $9.40 Million Stock Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
CDK2/cyclin E1 inhibitors disclosed in Incyte patent - BioWorld Online
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Principal Financial Group Inc. Has $14.59 Million Holdings in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte Corp. stock rises Tuesday, still underperforms market - MarketWatch
Is Incyte Stock Outperforming The Dow? - Barchart
Is Incyte Stock Outperforming the Dow? - Inkl
Franklin Resources Inc. Sells 50,188 Shares of Incyte Co. (NASDAQ:INCY) - MarketBeat
Sanctuary Advisors LLC Has $1.51 Million Stake in Incyte Co. (NASDAQ:INCY) - MarketBeat
Incyte price target raised to $70 from $68 at Wells Fargo - Yahoo Finance
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
The Analyst Verdict: Incyte In The Eyes Of 15 Experts - Benzinga
Wells Fargo & Company Issues Positive Forecast for Incyte (NASDAQ:INCY) Stock Price - MarketBeat
Analysts Set Incyte Co. (NASDAQ:INCY) Target Price at $76.18 - MarketBeat
Incyte corp principal accounting officer Tray Thomas sells $90,967 in stock - Investing.com India
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.62%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):